| Noncontrolling Interest Disclosure [Text Block] |
Note 16. Non-controlling interests
The following are majority-owned subsidiaries of the Company and the percentage of ownership interest maintained by the Company is set forth in the parenthetical: Enroot (75%), Aphria Diamond (51%), and Colcanna S.A.S. (90%).
The following table provides a summary of certain balance sheet information before intercompany eliminations relating to the above-referenced majority-owned subsidiaries of the Company in which there was a non-controlling interest as of February 28, 2026:
| | | | | | | Aphria | | | ColCanna | | | February 28, | |
| | | Enroot | | | Diamond | | | S.A.S. | | | 2026 | |
| Current assets | | $ | 202 | | | $ | 75,233 | | | $ | 2 | | | $ | 75,437 | |
| Non-current assets | | | — | | | | 107,522 | | | | 3,759 | | | | 111,281 | |
| Current liabilities | | | (12 | ) | | | (127,190 | ) | | | (7,115 | ) | | | (134,317 | ) |
| Non-current liabilities | | | | | | | (31,504 | ) | | | (1,442 | ) | | | (32,946 | ) |
| Net assets | | $ | 190 | | | $ | 24,061 | | | $ | (4,796 | ) | | $ | 19,455 | |
The following table provides a summary of certain balance sheet information before intercompany eliminations relating to the above-referenced majority-owned subsidiaries of the Company in which there was a non-controlling interest as of May 31, 2025:
| | | SH | | | CC Pharma | | | Aphria | | | ColCanna | | | May 31, | |
| | | Acquisition | | | Nordic ApS | | | Diamond | | | S.A.S. | | | 2025 | |
| Current assets | | $ | — | | | $ | — | | | $ | 83,390 | | | $ | 20 | | | $ | 83,410 | |
| Non-current assets | | | — | | | | — | | | | 114,677 | | | | 3,348 | | | | 118,025 | |
| Current liabilities | | | — | | | | — | | | | (126,986 | ) | | | (6,953 | ) | | | (133,939 | ) |
| Non-current liabilities | | | — | | | | — | | | | (31,720 | ) | | | (1,442 | ) | | | (33,162 | ) |
| Net assets | | $ | — | | | $ | — | | | $ | 39,361 | | | $ | (5,027 | ) | | $ | 34,334 | |
The following table provides a summary of certain income statement information before intercompany eliminations relating to the above referenced majority-owned subsidiaries of the Company in which there was a non-controlling interest for the nine months ended February 28, 2026:
| | | | | | | Aphria | | | ColCanna | | | February 28, | |
| | | Enroot | | | Diamond | | | S.A.S. | | | 2026 | |
| Revenue | | $ | 27 | | | $ | 46,946 | | | $ | — | | | $ | 46,973 | |
| Total expenses | | | 37 | | | | 37,696 | | | | (653 | ) | | | 37,080 | |
| Net (loss) income | | | (10 | ) | | | 9,250 | | | | 653 | | | | 9,893 | |
| Other comprehensive (loss) income | | | — | | | | (72 | ) | | | (422 | ) | | | (494 | ) |
| Net comprehensive (loss) income | | $ | (10 | ) | | $ | 9,178 | | | $ | 231 | | | $ | 9,399 | |
| Non-controlling interest % | | | 25 | % | | | 49 | % | | | 10 | % | | NA | |
| Comprehensive (loss) income attributable to NCI | | | (3 | ) | | | 4,497 | | | | 23 | | | | 4,517 | |
| Net comprehensive (loss) income attributable to NCI | | $ | (3 | ) | | $ | 4,497 | | | $ | 23 | | | $ | 4,517 | |
The following table provides a summary of certain income statement information before intercompany eliminations relating to the above referenced majority-owned subsidiaries of the Company in which there was a non-controlling interest for the nine months ended February 28, 2025:
| | | SH | | | CC Pharma | | | Aphria | | | ColCanna | | | February 28, | |
| | | Acquisition | | | Nordic ApS | | | Diamond | | | S.A.S. | | | 2025 | |
| Revenue | | $ | — | | | $ | — | | | $ | 53,608 | | | $ | — | | | $ | 53,608 | |
| Total expenses | | | 20,000 | | | | 6 | | | | 39,557 | | | | 62 | | | | 59,625 | |
| Net (loss) income | | | (20,000 | ) | | | (6 | ) | | | 14,051 | | | | (62 | ) | | | (6,017 | ) |
| Other comprehensive (loss) income | | | — | | | | 3 | | | | (1,568 | ) | | | 127 | | | | (1,438 | ) |
| Net comprehensive (loss) income | | $ | (20,000 | ) | | $ | (3 | ) | | $ | 12,483 | | | $ | 65 | | | $ | (7,455 | ) |
| Non-controlling interest % | | | 32 | % | | | 25 | % | | | 49 | % | | | 10 | % | | NA | |
| Comprehensive (loss) income attributable to NCI | | | (6,400 | ) | | | (1 | ) | | | 6,117 | | | | 7 | | | | (277 | ) |
| Net comprehensive (loss) income attributable to NCI | | $ | (6,400 | ) | | $ | (1 | ) | | $ | 6,117 | | | $ | 7 | | | $ | (277 | ) |
|